Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.
COVID-19
Coronavirus disease 2019
Ivermectin
SARS-CoV-2
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
05 Feb 2022
05 Feb 2022
Historique:
received:
29
09
2021
accepted:
23
01
2022
entrez:
6
2
2022
pubmed:
7
2
2022
medline:
11
2
2022
Statut:
epublish
Résumé
The global COVID-19 pandemic has affected the world's population by causing changes in behavior, such as social distancing, masking, restricting people's movement, and evaluating existing medication as potential therapies. Many pre-existing medications such as tocilizumab, ivermectin, colchicine, interferon, and steroids have been evaluated for being repurposed to use for the treatment of COVID-19. None of these agents have been effective except for steroids and, to a lesser degree, tocilizumab. Ivermectin has been one of the suggested repurposed medications which exhibit an in vitro inhibitory activity on SARS-CoV-2 replication. The most recommended dose of ivermectin for the treatment of COVID-19 is 150-200 µg/kg twice daily. As ivermectin adoption for COVID-19 increased, the Food and Drug Administration (FDA) issued a warning on its use during the pandemic. However, the drug remains of interest to clinicians and has shown some promise in observational studies. This narrative reviews the toxicological profile and some potential therapeutic effects of ivermectin. Based on the current dose recommendation, ivermectin appears to be safe with minimum side effects. However, serious questions remain about the effectiveness of this drug in the treatment of patients with COVID-19.
Identifiants
pubmed: 35123559
doi: 10.1186/s40001-022-00645-8
pii: 10.1186/s40001-022-00645-8
pmc: PMC8817475
doi:
Substances chimiques
Antiviral Agents
0
Ivermectin
70288-86-7
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Informations de copyright
© 2022. The Author(s).
Références
Vet J. 2009 Jan;179(1):25-37
pubmed: 17851096
J Clin Pharmacol. 2002 Oct;42(10):1122-33
pubmed: 12362927
Head Neck. 2020 Jun;42(6):1252-1258
pubmed: 32342566
Trends Parasitol. 2017 Jun;33(6):463-472
pubmed: 28285851
Int J Pharm. 2004 Jun 11;277(1-2):3-9
pubmed: 15158963
Avicenna J Med Biotechnol. 2020 Oct-Dec;12(4):246-250
pubmed: 33014317
Am J Ther. 2021 Apr 22;28(3):e299-e318
pubmed: 34375047
Cells. 2020 Sep 15;9(9):
pubmed: 32942671
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Euro Surveill. 2020 Feb;25(5):
pubmed: 32019636
Chest. 2021 Jan;159(1):85-92
pubmed: 33065103
J Infect Dis. 2020 Aug 4;222(5):734-745
pubmed: 32563187
Am J Trop Med Hyg. 2020 Jun;102(6):1156-1157
pubmed: 32314704
Mayo Clin Proc. 2020 Jul;95(7):1454-1466
pubmed: 32561148
Int J Antimicrob Agents. 2020 Aug;56(2):106080
pubmed: 32634603
Eur J Neurol. 2021 Oct;28(10):3426-3436
pubmed: 33417287
Cureus. 2020 Aug 24;12(8):e10004
pubmed: 32983701
New Microbes New Infect. 2020 Apr 22;35:100684
pubmed: 32322397
Ann Dermatol Venereol. 2006 Oct;133(10):784-7
pubmed: 17072195
PLoS Negl Trop Dis. 2018 Jan 18;12(1):e0006020
pubmed: 29346388
J Pharm Pharm Sci. 2020;23:462-469
pubmed: 33227231
Clin Pharmacol Ther. 2020 Oct;108(4):762-765
pubmed: 32378737
AAPS J. 2008;10(1):42-6
pubmed: 18446504
PLoS Negl Trop Dis. 2018 Nov 19;12(11):e0006934
pubmed: 30452439
Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130
pubmed: 32363212
PLoS One. 2021 Feb 16;16(2):e0247163
pubmed: 33592050
Nat Rev Microbiol. 2004 Dec;2(12):984-9
pubmed: 15550944
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
Clin Nurse Spec. 2022 Jan-Feb 01;36(1):16-19
pubmed: 34843190
EClinicalMedicine. 2021 Feb;32:100720
pubmed: 33495752
Eur J Pharmacol. 2020 Sep 15;883:173372
pubmed: 32682787
Open Forum Infect Dis. 2021 Jul 06;8(11):ofab358
pubmed: 34796244
Am J Trop Med Hyg. 2018 Feb;98(2):382-388
pubmed: 29210346
J Antimicrob Chemother. 2020 Apr 1;75(4):827-834
pubmed: 31960060
Curr Res Transl Med. 2021 Oct;69(4):103309
pubmed: 34418758
J Antibiot (Tokyo). 2020 Sep;73(9):593-602
pubmed: 32533071
Vet Parasitol. 2005 Mar 31;128(3-4):251-60
pubmed: 15740862
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830
pubmed: 33994641
Cochrane Database Syst Rev. 2016 Jan 18;(1):CD007745
pubmed: 26778150
In Vivo. 2020 Sep-Oct;34(5):3023-3026
pubmed: 32871846
Cell Rep. 2020 Sep 22;32(12):108185
pubmed: 32941788
Appl Microbiol Biotechnol. 2021 Feb;105(4):1333-1343
pubmed: 33515285
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
BMC Pharmacol Toxicol. 2017 May 4;18(1):20
pubmed: 28468637
Clin Infect Dis. 2014 Jan;58(1):143-4
pubmed: 24065325
Malar J. 2017 Apr 24;16(1):161
pubmed: 28434401
Turk J Med Sci. 2020 Apr 15;50(SI-1):611-619
pubmed: 32293834
Cell Death Differ. 2020 Dec;27(12):3209-3225
pubmed: 33037393
J Infect Chemother. 2021 Dec;27(12):1743-1749
pubmed: 34483029
Dermatol Ther (Heidelb). 2019 Dec;9(4):623-630
pubmed: 31512176
Int J Dermatol. 2005 Dec;44(12):981-8
pubmed: 16409259
Int J Antimicrob Agents. 2021 Jan;57(1):106248
pubmed: 33259913
Chem Biol Interact. 2001 Aug 31;137(2):155-67
pubmed: 11551531
Lancet Infect Dis. 2018 Jun;18(6):615-626
pubmed: 29602751
JAMA. 2021 Apr 13;325(14):1426-1435
pubmed: 33662102
Lancet Infect Dis. 2021 Jan;21(1):24-25
pubmed: 32437697
Trans R Soc Trop Med Hyg. 2004 Aug;98(8):496-504
pubmed: 15186939
Filaria J. 2003 Oct 24;2 Suppl 1:S3
pubmed: 14975060
PLoS One. 2020 Nov 11;15(11):e0242184
pubmed: 33175880
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1153-1156
pubmed: 32462282
Trop Med Int Health. 2003 Sep;8(9):820-31
pubmed: 12950668
Subst Abuse Treat Prev Policy. 2020 Dec 3;15(1):91
pubmed: 33272308
Filaria J. 2003 Oct 24;2 Suppl 1:S4
pubmed: 14975061
JMIR Public Health Surveill. 2020 Apr 30;6(2):e19160
pubmed: 32320381
Indian J Tuberc. 2020 Jul;67(3):448-451
pubmed: 32825892
Trends Parasitol. 2014 Sep;30(9):445-55
pubmed: 25130507
J Antibiot (Tokyo). 2022 Feb;75(2):122
pubmed: 34127807
Brain Behav Immun. 2017 Feb;60:1-12
pubmed: 26995317
Cell Discov. 2020 Sep 15;6:65
pubmed: 32953130